EurekaBio Raises $40M To Support Lentiviral Vector Platform


Key Topics in this News Article:

News Snapshot:

BlackJack3D Deals and Financings Shenzhen EurekaBio closed a $40 million Series B+ funding to support the commercialization of its EuLV™ Lentiviral Vector Production System, a technology that the company believes could transform large-scale production of lentiviral vectors. The system is based on stable cell lines and a serum-free suspension system. Eureka believes its novel technology will have a major impact in how cell and gene therapies are developed. The B+ round was led by Yeuxiu Industrial Fund, with participation from China funds and follow-on investments from US funds. Chengdu Maxvax Biotechnology raised $40 million in a Series C financing round...